Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
Shareholders that lost money on Vertex Pharmaceuticals Incorporated(VRTX) should contact Levi & Korsinsky about Securities Fraud Investigation - VRTX
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...
Vertex’s non-opioid drug succeeds in back pain trial
Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...
STAT12d
Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study
A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.
Yahoo Finance10d
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Vertex Pharmaceuticals (NASDAQ ... Image source: Getty Images. First, let's consider the Vertex story so far. The company has built a CF empire, offering several treatments known as CFTR modulators.